Stocks of the Hour: Lake Resources, Talon Energy, Actinogen Medical
Stocks of the Hour: Lake Resources, Talon Energy, Actinogen Medical
Lake Resources (ASX:LKE) has announced a successful completion of the lithium carbonate test program, which is an important milestone towards the completion of DFS. In response,
萊克資源公司(澳大利亞證券交易所股票代碼：LKE)宣佈碳酸鋰測試專案成功完成，這是邁向DFS完成的一個重要里程碑。作為回應，
Lake CEO David Dickson said, "most DLE lithium carbonate announcements are based on a few kilograms of carbonate produced on a lab bench scale unit; we've produced more lithium carbonate than most DLE projects under development. This gives us great confidence in our process." Shares are trading 7.58 per cent higher at 17.75 cents.
萊克首席執行官David·迪克森表示：“大多數DLE碳酸鋰公告都是基於實驗室規模裝置生產的幾公斤碳酸鋰；我們生產的碳酸鋰比大多數正在開發的DLE專案都多。這給了我們對我們過程的巨大信心。”該公司股價上漲7.58%，至17.75美分。
Talon Energy (ASX:TPD) has announced that the Walyering gas field development, in which Talon owns 45 per cent, has commenced production. In response, Mr Colby Hauser, Talon's Managing Director and Chief Executive Officer commented: "Transitioning from Explorer to Producer has been an important milestone for the business. We look forward to working with Strike and supplying firm gas into our gas sales agreement with Santos." Shares are trading 1.28 per cent higher at 19.75 cents.
塔龍能源(澳大利亞證券交易所股票代碼：TPD)宣佈，塔龍擁有45%股份的Walyering氣田開發專案已開始投產。對此，塔龍董事的董事總經理兼首席執行官科爾比·豪澤先生評論道：“從勘探公司到生產商的轉變對公司來說是一個重要的里程碑。我們期待著與Strike合作，並在我們與桑托斯的天然氣銷售協定中提供公司的天然氣。”該公司股價上漲1.28%，至19.75美分。
Actinogen Medical (ASX:ACW) announced enhancement of the design of the XanaMIA Phase 2b trial in patients with mild-to-moderate Alzheimer's disease to reduce the cost and time to initial results. The current FDA-approved three-arm trial was designed to confirm the safety, pro-cognitive and clinical benefits of Xanamem and explore two dose levels, in what is called 'dose-ranging.' Shares are trading 5.56 per cent higher at 1.9 cents.
亞洲網加利福尼亞州聖克拉拉10月23日電Actinogen Medical(澳大利亞證券交易所市場代碼：ACW)宣佈，改進了針對輕、中度阿爾茨海默病患者的XanaMIA 2b期試驗的設計，以降低成本並縮短初見成效的時間。目前FDA批准的這項三組試驗旨在確認Xanamem的安全性、促進認知和臨床益處，並探索兩個劑量水準，即所謂的“劑量範圍”。該公司股價上漲5.56%，至1.9美分。
